Regenerative Medical Technology Group Expands ISSCA AI Clinical Intelligence Platform
News related to:Regenerative Medical Technology Group, Inc · 2 min read
Regenerative Medical Technology Group, Inc. has unveiled an expanded version of its ISSCA AI™ Clinical Intelligence Platform, designed to streamline the process of regenerative and longevity medicine for clinics and physicians. The updated platform, which is being developed under the auspices of the International Society for Stem Cell Application (ISSCA), aims to provide a more integrated and physician-controlled system for generating tailored intervention plans based on patient data.
The new ISSCA AI™ platform allows physicians to upload laboratory PDFs, which are then processed by the AI engine, Florence, to extract biomarkers, compute biological age and system-level risk scores, and draft a tailored intervention plan for physician review. This workflow is intended to reduce the time required for documentation and decision-making, making it easier for healthcare providers to implement personalized treatment plans.
According to the company, the platform is designed to benefit from ISSCA's established international infrastructure, global physician network, and longstanding business relationships. The system is intended to support ISSCA's certified-physician network across more than 30 countries, providing a clear pathway for integrating cutting-edge technology into the existing ecosystem.
The ISSCA AI™ platform is being developed around four complementary commercial channels designed to support adoption, recurring revenue generation, and long-term platform expansion. These channels include SaaS subscriptions, patient longevity memberships, a conference-based commercial channel, and ISSCA AI™ Certification, a faculty-led education and credentialing program.
The SaaS subscriptions will be distributed through ISSCA's established certified-physician network, enabling participating clinics to develop recurring, technology-enabled relationships with their patients. The patient longevity memberships are intended to foster ongoing engagement between clinics and patients, creating a sustainable revenue stream. The conference-based commercial channel will leverage ISSCA's international events for live demonstrations, customer acquisition, onboarding, and implementation support. Finally, the ISSCA AI™ Certification program is designed to accelerate physician adoption and function as a separate revenue-generating offering.
David Christensen, CEO and President of Regenerative Medical Technology Group, Inc., stated, "The important change is simple: ISSCA AI™ is being built around the way our doctors already practice. We are building toward a physician uploading a lab report and getting a clear plan to review in minutes, using ISSCA's own methods, with the doctor still making every decision. We believe that is what turns this from a generic tool into something that matters, something that our network can actually use daily."
The company's technology developer has stated that the reasoning corpus of the ISSCA AI™ platform comprises 1.6 million longitudinal electronic health records spanning 30 years of patient history, together with more than 10,000 clinical studies. The platform is described as HIPAA-aligned and designed for protected health information and clinic-grade privacy. The operating principle remains physician-in-the-loop: the system is designed to suggest, and the physician approves. Florence is designed to decline an answer rather than fabricate one when it cannot support a clinically relevant response.
Regenerative Medical Technology Group, Inc. operates through Global Stem Cells Group and its subsidiaries, combining physician education, laboratory operations, biologics manufacturing, and product distribution in permitted international markets. The company operates across more than 30 countries and is committed to advancing the clinical application of regenerative medicine and cellular therapies.